Please ensure Javascript is enabled for purposes of website accessibility

3 Dependable Dividend Stocks to Buy in April

By Zhiyuan Sun - Updated Apr 3, 2021 at 12:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking for a steady stream of income? These are companies you can count on.

Stocks that pay dividends are becoming rarer and rarer. Corporate management teams often opt to retain earnings for the sake of growth instead of returning it to shareholders. This is problematic for investors who want to see steady streams of cash flowing into their portfolios every once in a while. 

What's more, the S&P 500's dividend yield has fallen to a meager 1.53% per year. Luckily, individual stocks such as Automatic Data Processing (ADP 2.92%)Innovative Industrial Properties (IIPR 2.37%), and Merck & Co (MRK 0.83%) all have substantial yields, especially compared to that of the index. Let's look at why they are ideal choices for dividend investors.

Man analyzing income statements.

Image source: Getty Images.

1. Automatic Data Processing

For six years in a row, Automatic Data Processing (ADP) has been the top human resource (HR) product winner in Human Resource Executive. The company has over 860,000 clients worldwide in every industry, managing payroll, HR, and employer tax deductions.

This year, ADP expects to increase its revenue by 1% to 3% to $14.59 billion, and leave its earnings per share (EPS) unchanged. At the moment, the company generates close to $1.2 billion each year in cash flow from operations, which is more than enough to pay for its $81 million in capital expenditures and $781.7 million in dividends. Its stock's price-to-earnings (P/E) ratio of 32 is lower than the S&P 500's 40.3, and it offers a higher yield of 1.94%.

2. Innovative Industrial Properties

Innovative Industrial Properties has become a mega landlord in the rising cannabis industry. Aside from leasing out dispensaries/cultivation/distribution facilities to growers, it has an innovative business model that utilizes sale-leaseback programs. Basically, the company acquires stores from reputable marijuana growers like Harvest Health & Recreation Inc (HRVSF), and then rents them back to the sellers. This way pot growers get lump sums of cash to expand their businesses, while Innovative Industrial receives a steady stream of rent checks, creating a win-win situation.

It typically pays $5 million to $30 million for each dispensary, with an average lease period of 10 to 20 years, and receives 10% to 16% of the transaction value each year in rental income. Today, Innovative Industrial manages 67 properties across 17 states, with an average lease length of 16.7 years. Its facilities are 100% leased, with 100% of rent paid on time. The company is also well-capitalized, with a debt-to-asset ratio of just 7.9%.

Innovative Industrial generates about $148.4 million per year in sales, and pays a dividend of $4.96 per share based on Q4 2020 annualized rates. Last year it more than tripled its adjusted funds from operations (AFFO) to $97.8 million, which amounts to about $4.08 per share.

If the difference between its dividend payout and its AFFO looks sketchy, it really isn't. At this growth rate, the company should be more than capable of meeting its long-term payout ratio of 75% to 85% dividends/AFFO. With a dividend yield of 2.57% and a P/E ratio of 57, Innovative is simultaneously the most expensive stock on our list and the one with the most growth potential.

3. Merck & Co

Last year, Merck's business took a hit as patients took a step back from discretional health products due to the effects of the COVID-19 pandemic. Its revenue increased by 2% year over year to $48 billion, while its earnings fell sharply by 28% compared to 2019 levels, to $7.082 billion.

What saved Merck was a strong sales performance by its miracle immunotherapy cancer treatment, Keytruda. In the past two years, Keytruda's revenue doubled to $14.38 billion. The popular cancer treatment has seven years' room to grow further before its patents expire in 2028.

In addition, the company has over 20 therapeutic candidates in phase 3 trials to offset Keytruda's lost cash flows after it goes off-patent. The most promising is a potential multi-billion dollar HIV collaboration program with Gilead Sciences (GILD 0.51%).

Right now, Merck generates $2.77 in EPS, which is more than enough to cover the $2.48 per share it pays out in dividends. Trading at 27 times P/E with a solid dividend yield of 3.27%, this is an income-generating pharma stock trading at a bargain price.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$93.08 (0.83%) $0.77
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$64.80 (0.51%) $0.33
Automatic Data Processing, Inc. Stock Quote
Automatic Data Processing, Inc.
ADP
$224.66 (2.92%) $6.38
Innovative Industrial Properties Stock Quote
Innovative Industrial Properties
IIPR
$133.09 (2.37%) $3.08
Harvest Health & Recreation Inc. Stock Quote
Harvest Health & Recreation Inc.
HRVSF

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.